RBR-26m455f招募中3 期
Phase 3, Single Arm, Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Injectable Suspension (TOL2506) in Combination with Endocrine Therapy in Premenopausal Subjects with Hormone-Receptor–Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer
Fundação do ABC - Faculdade de Medicina do ABC0 个研究点开始时间: 2023年4月18日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18Y 至 49Y（—）
入选标准
- •Female: Able to understand the investigational nature of this study and provide written informed consent prior to the participation in the trial; Age 18 to 49, inclusive; Diagnosis of Stage I, II, or III HR+, HER2-negative breast cancer (ER>1% and/or, PR>1%, HER2-negative per ASCO CAP guidelines); Is a candidate for endocrine therapy + ovarian suppression; LH > 4 IU/L within 28 days prior to Day 1; Is premenopausal as defined by:E2 > 30 pg/mL; follicle-stimulating hormone (FSH) < 40 IU/L; regular menses (eg, menstrual cycle length of 21 to 35 days). Note: premenopausal status must be determined before neo/adjuvant chemotherapy in patients for which it is planned or prior to Day 1 in patients who did not have prior chemotherapy. If premenopausal status was not determined prior to chemotherapy, E2 and FSH must meet the above criteria when measured 2 weeks or more after the end of the final cycle of chemotherapy. Male: Able to understand the investigational nature of this study and provide written informed consent prior to participation in the trial; Age 18 or older; Diagnosis of Stage I, II, or III HR+, HER2-negative breast cancer (ER>1% and/or, PR>1%, HER2-negative per ASCO CAP guidelines); Is a candidate for endocrine therapy + GnRH agonist
排除标准
- •Female: Body mass index (BMI) < 18.00 kg/m2 or > 35.00 kg/m2. Breastfeeding. Life expectancy < 12 months. Eastern Cooperative Oncology Group (ECOG) performance status =3. Unacceptable hepatic function as determined by any of the following: Alanine aminotransferase (ALT) = 2X upper limit of normal (ULN); Aspartate aminotransferase (AST) = 2X ULN; Bilirubin = 2X ULN; Alkaline phosphatase = 2X ULN; Severe hepatic impairment (Child-Pugh Class C). Unacceptable renal function as determined by any of the following: Creatinine = 3X ULN; Creatinine clearance = 30 mL/minute; Creatinine clearance = 60 mL/minute in subjects with bone density 1.5 standard deviations below the young adult normal mean. History of significantly abnormal ECG or screening 12-lead ECG demonstrating any of the following: HR > 100 BPM; QRS > 120 msec; QTc > 450 msec; PR > 220 msec. Prior (within 28 days prior to Day 1) and/or concomitant use of medications known to prolong the QT/QTc interval. Prior use of tamoxifen, other SERMs (eg, raloxifene) or antagonists (eg, fulvestrant), aromatase inhibitor, mammalian target of rapamycin (mTOR) inhibitors, or hormone replacement therapy within 3 months before breast cancer diagnosis. Concomitant use of anticancer mediations other than those specified for use by the protocol. Prior neoadjuvant or adjuvant endocrine therapy since diagnosis of breast cancer. History of treatment for osteopenia/osteoporosis. Prior (within 6 months prior to Day 1) or current use of drugs known to increase bone mineral density (ie, bisphosphonates, denosumab, teriparatide, abaloparatide, romosozumab) or use of supplements known to increase bone mineral density (ie, calcitonin, fluoride, strontium) within 28 days prior to Day 1. Low trauma fracture(s) occurring within 12 months prior to subject’s first visit (defined as a fracture that results from a fall from a standing height or less, excluding fingers, toes, face and skull). Conditions that preclude bone mineral density measurement (lumbar spine/bilateral hip surgery with hardware in place, abdominal clips, umbilical ring [not willing to remove] or weight that exceeds the DEXA machine limitation). Any other medical condition or serious illness, presence of a second malignancy under current treatment or follow-up, or the presence of clinically significant findings on the physical exam, laboratory testing, medical history (including conditions that may be associated with low bone mass), that in the opinion of the Investigator may interfere with trial conduct, subject safety, or interpretation of study results. Already receiving and/or previously received GnRH analogs within 1 year before breast cancer diagnosis. Psychiatric, addictive, or other disorders that would preclude study compliance. Use of medications that may impact subject safety and/or affect the PK of the drug and hormonal assessments including but not limited to: Oral or transdermal hormonal therapy within 30 days prior to subject’s first visit; Estrogen, progesterone, or androgens within 30 days prior to subject’s first visit; Hormonal contraceptives within 30 days prior to subject’s first visit; Medications known to result in clinically important decreases in bone mass taken within 6 months prior to subject’s first visit. Known hypersensitivity, idiosyncratic, or allergic reactions to GnRH, GnRH agonist/analogs or to any of the components of the IP. Sexually active with a male partner and not willing to use non-hormonal contraceptive metho
研究者
相似试验
尚未招募
3 期
A Phase 3 Study of Three-Month Leuprolide Acetate For Injectable Suspension (TOL2506) in Combination with Endocrine Therapy in Premenopausal Subjects with (HR+), (HER2)-Negative Breast Cancer.CTRI/2024/07/070855Tolmar, Inc.
进行中（未招募）
3 期
A study to investigate the safety, pharmacokinetics, occurrence of anti-drug antibody, and anti-RSV neutralizing antibody following 2 doses administration of nirsevimab (MEDI8897) in infants with certain health conditions or born pre-term in JapaJPRN-jRCT2031230256jRCT Inquiries IQVIA contact person33
进行中（未招募）
1 期
Phase 2/3 study of Remdesivir in patients from birth to <18 years old with COVID-19Coronavirus disease 2019 (COVID-19)MedDRA version: 23.0Level: PTClassification code 10051905Term: Coronavirus infectionSystem Organ Class: 10021881 - Infections and infestationsEUCTR2020-001803-17-GBGilead Sciences Inc.52
进行中（未招募）
1 期
Phase 2/3 study of Remdesivir in patients from birth to <18 years old with COVID-19EUCTR2020-001803-17-ITGILEAD SCIENCES INCORPORATED52
进行中（未招募）
1 期
A Phase 3 study to evaluate the efficacy and safety of BMN 270 gene transfer in patients with severe hemophilia AHaemophilia AMedDRA version: 20.0Level: LLTClassification code 10060612Term: Hemophilia ASystem Organ Class: 100000004850EUCTR2017-003215-19-FRBioMarin Pharmaceutical Inc.130